Due to therapeutic challenges, hospital-acquired infections (HAIs) caused by Acinetobacter baumannii (HA-AB), particularly carbapenem-resistant strains (HA-CRAB) pose a serious health threat to patients worldwide. This systematic review sought to summarize recent data on the incidence and prevalence of HA-AB and HA-CRAB infections in the WHOdefined regions of Europe (EUR), Eastern Mediterranean (EMR) and Africa (AFR). A comprehensive literature search was performed using MEDLINE, EMBASE and GMI databases (01/2014-02/2019). Random-effects meta-analyses were performed to determine the pooled incidence of HA-AB and HA-CRAB infections as well as the proportions of A. baumannii among all HAIs. 24 studies from 3,340 records were included in this review (EUR: 16, EMR: 6, AFR: 2). The pooled estimates of incidence and incidence density of HA-AB infection in intensive care units (ICUs) were 56.5 (95% CI 33.9-92.8) cases per 1,000 patients and 4.4 (95% CI 2.9-6.6) cases per 1,000 patient days, respectively. Five studies conducted at a hospital-wide level or in specialized clinical departments/wards (ICU + non-ICU patients) showed HA-AB incidences between 0.85 and 5.6 cases per 1,000 patients. For carbapenem-resistant A. baumannii infections in ICUs, the pooled incidence and incidence density were 41.7 (95% CI 21.6-78.7) cases per 1,000 patients and 2.1 (95% CI 1.2-3.7) cases per 1,000 patient days, respectively. In ICUs, A. baumannii and carbapenem-resistant A. baumannii strains accounted for 20.9% (95% CI 16.5-26.2%) and 13.6% (95% CI 9.7-18.7%) of all HAIs, respectively. Our study highlights the persistent clinical significance of hospital-acquired A. baumannii infections in the studied WHO regions, particularly in ICUs.
Introduction
Acinetobacter spp. are non-fermenting, largely opportunistic Gram-negative bacteria that are ubiquitous in the environment. Acinetobacter baumannii complex (Acinetobacter nosocomialis, Acinetobacter pitti and Acinetobacter baumannii) are the most clinically significant out of the over 50 species in the Acinetobacter genus [1] . Of all Acinetobacter species, A. baumannii sensustricto (shortened to A. baumannii) is responsible for about 90% of the clinical infections caused by Acinetobacter spp. in humans [1] . Infections from A. baumannii, in particular carbapenem-resistant A. baumannii (CRAB), are of significant public health importance worldwide because of their association with high treatment costs, mortality and morbidity [2, 3] . The World Health Organization (WHO) has ranked carbapenem-resistant A. baumannii as a critical priority pathogen on its global priority list of antibiotic-resistant bacteria to guide drug research and development [4] . Worldwide, CRAB has been implicated in several hospital outbreaks of diseases like pneumonia, bloodstream, wound and urinary tract infections, especially among patients with severe morbidities such as those staying in ICU [5, 6] . The pathogen is able to survive adverse environmental conditions, fostering its persistence and spread in the hospital environment [7, 8] . Treating carbapenem-resistant A. baumannii infections is very challenging since they are naturally resistant to antibiotics in the WHO "Access" and "Watch" list. They are therefore associated with poor clinical outcomes across many healthcare settings [9] . Multiple studies have been conducted worldwide to analyses the burden of healthcare-associated infections caused by A. baumannii. Depending on the variables under study (e.g. study location, included patient cohorts and clinical wards), the incidence or prevalence estimates of (carbapenem-resistant) A. baumannii vary significantly between the different studies. Even though representative data are scarce, there is evidence for increasing incidence of A. baumannii outbreaks in healthcare facilities across Sub-Saharan Africa and Eastern Mediterranean countries, both of which have diverse populations [10, 11] . Moreover, the epidemiological situation has worsened in Europe as it has become endemic in the south and eastern parts of Europe with some areas experiencing cross-border transmission [1] .
To our knowledge, no systematic review on the frequency of (carbapenem-resistant) A. baumannii across Europe, the Eastern Mediterranean Region and Africa has been published. A comprehensive understanding of the current epidemiological picture is therefore needed. This systematic review aims to comprehensively analyse recent data on the prevalence and incidence of hospital-acquired infections with (carbapenem-resistant) A. baumannii to better understand the current epidemiology in these WHO-defined regions. This will help with the development of context-specific prevention and control interventions against this dangerous and increasingly untreatable pathogen.
Materials and methods
This systematic review was registered in the Prospective Register of Systematic Reviews (PROSPERO; registration no. CRD42019124503) and conducted using the PRISMA checklist [12] .
Search strategy
In order to identify recent studies on the burden of hospital-acquired A. baumannii infections, we performed a systematic literature search using the electronic databases MEDLINE, EMBASE, and The Global Index Medicus (GIM) for studies from January 2014 up to February 2019. For the search strings, we used a combination of synonyms of hospital-acquired infections and Acinetobacter baumannii (see additional file 1). Title and abstract screening and full text review of potentially eligible studies were carried out independently by two researchers (R. M. and O. A.). All discrepancies regarding the inclusion were resolved through discussion.
Inclusion / exclusion criteria
We included epidemiological studies that provide data on the prevalence and/or incidence of HA-AB and HA-CRAB infections, regardless of whether the studies were retrospective or prospective. Studies were eligible if they reported relevant data from patient cohorts from entire hospitals or individual clinical departments/wards without selection of particular diseases or patient sub-groups. Studies were only included if they were conducted in the following WHO regions:
African Region (AFR), Eastern Mediterranean Region (EMR) and European Region (EUR). A study was eligible if it provided a clear distinction between A. baumannii infections acquired in the hospital and community. Only studies written in English, German and French were eligible. Since this systematic review focused on recent epidemiological A. baumannii data, studies published before 2014 and studies that completed data collection before 2009 were excluded. Studies with any of the following study design/study type were excluded: Reviews, systematic reviews, editorials, letters, commentaries, conference abstracts, case reports, case-control studies and randomized controlled trials (RCTs). Studies were excluded if no clear distinction was made between A. baumannii infection and colonization status.
Data extraction and outcomes of interest
Two authors (R. M. and O. A.) independently extracted data using a standard extraction form. Any discrepancies were resolved through discussion. The primary outcome was the prevalence and/or incidence of hospital-acquired (carbapenem-resistant) A. baumannii infections among (i) all patients in the hospital or individual departments/wards and (ii) among all hospitalacquired infections (HAIs). The prevalence refers to the number of HA-(CR)AB cases per 1,000 patients present in the hospital or ward at a given time point. The incidence refers to the number of new cases acquiring a HA-(CR)AB infection per 1,000 patients followed-up for a defined period of time. Other primary outcome parameters of interest were incidence density and population-based estimates of HA-AB and HA-CRAB infections. Secondary outcomes were attributable mortality and/or lethality as well as morbidity of HA-AB and HA-CRAB infections. A case of A. baumannii infection was categorized as "carbapenemresistant" when stated so by the authors of the study or when carbapenem resistance data of A. baumannii isolates were provided in the studies. If antimicrobial susceptibility testing showed resistance for at least one carbapenem (such as meropenem, imipenem), the isolate was categorized as carbapenem-resistant. In addition to the a priori analysis plan outlined in the study protocol, we also performed subgroup analyses, stratifying countries according to income level as defined by the World Bank (https://datatopics.worldbank.org/world-developmentindicators/stories/the-classification-of-countries-by-in come.html).
Risk of bias assessment and statistical analysis
All included studies were assessed for risk of bias by two review authors (R.M. and O.A.). Disagreements were resolved through discussion. The risk of bias tool developed by Hoy et al. was used, which is specific for the study designs of the included studies [13] . In order to calculate pooled incidences and incidence densities, raw proportions were logit transformed [14] . For all analyses, random-effects models with inverse variance weighting were used. The I 2 statistic was used to estimate inter-study heterogeneity. All statistical analyses and forest plots visualizations were performed using R version 3.5.1 [15] with the "meta" (v. 4.9.5) and "metafor" (v. 2.1.0) packages.
Results
In total, 3,340 records were identified through our database search. Following screening of titles and abstracts, 178 potentially eligible studies were identified and included for full text review. Finally, 24 studies published between 2014 and 2018 were found eligible and therefore included in this systematic review ( Figure 1 ).
Study characteristics and risk of bias assessment
The study characteristics are summarized in Table 1 . Among the 24 included studies, 16 were conducted in the European region of the WHO. Of these, eight studies were carried out in Turkey. Six out of 24 studies were conducted in the Eastern Mediterranean region and two in the African region. The majority of studies were from upper-middle income (n = 11) and high income (n = 8) countries. Two studies reported prevalence data and 22 studies provided data on the incidence and/or incidence density of hospitalacquired A. baumannii infections. Just over half of the included studies (n = 13) were conducted exclusively on intensive care units (ICU). Five studies reported hospital-level data, while six studies were carried out in other wards or specialized clinic departments where both ICU and non-ICU patients are seen. The majority of studies (n = 16) also reported data on hospital-acquired infections with carbapenem-resistant A. baumannii. None of the included studies provided data on population-based incidence/prevalence or attributable mortality and morbidity.
Overall, risk of bias was low, as judged by the risk of bias tool by Hoy et al. (additional File 2, additional Fig.1 ) [13] . This is partly explained because, as per protocol, only epidemiological studies that included largely unselected patient cohorts from whole hospitals or individual departments/wards were eligible. The majority of studies (19 out of 24) used criteria from the Centers for Disease Control and Prevention / National Healthcare Safety Network (CDC/NHSN) or European Centre for Disease Prevention and Control (ECDC) to define hospital-acquired infections. The CDC/NHSN and ECDC definitions of HAIs are widely used and validated tools in the surveillance of healthcare-acquired infections. However, except for three multicenter studies that provided nationally representative estimates, the country representativeness was unclear or was not met in the majority of the included studies.
Incidence of hospital-acquired Acinetobacter baumannii infections
Based on data from 18 studies, the overall pooled incidence of hospital-acquired A. baumannii infections (HA-AB) in the WHO regions of Europe, Eastern Mediterranean and Africa is 25.1 (95% CI 12.8-48.5) cases per 1,000 patients ( Figure 2 ). However, the I 2 statistics indicates considerable statistical heterogeneity between the studies. In particular, incidence estimates differed substantially between studies that were conducted exclusively in intensive care units and studies that additionally included data from non-intensive care units. The pooled incidence of HA-AB infections in ICUs is 56.5 (95% CI 33.9-92.8) cases per 1,000 ICU patients. It is important to note that the between-study variation (I 2 = 99%, p < 0.01) was also substantial within the ICU-based study set. Further analyses revealed no statistically Compared to ICU-based estimates, incidences for HA-AB infections were up to 10 times smaller in three studies conducted in specialist clinical departments/wards where both ICU and non-ICU patients were seen. In these studies, HA-AB incidences ranged between 3.1 and 5.6 per 1,000 patients (pooled estimate: 4.2 [95% CI 2.7-6.6] per 1,000 patients). With a pooled incidence of 0.97 (95% CI 0.53-1.8) per 1,000 patients, the lowest HA-AB infection incidences were observed in hospital-wide studies.
Six studies reported data on the incidence density of hospital-acquired A. baumannii infections on ICUs expressed as HA-AB cases per 1,000 patient days. The pooled estimate was 4.4 (95% CI 2.9-6.6) HA-AB cases per 1,000 ICU patient days (Figure 3) . The individual study estimates ranged from 2.8 to 6.8 HA-AB cases per 1,000 ICU patient days, with a considerably high inter-study heterogeneity (I 2 = 96%, p < 0.01). One included study reported a hospital-wide incidence Patients with consecutive recorded bacterial and fungal isolates from an internal medicine ward CDC/NHSN criteria [22] 249 HAIs Figure 2 . Forest plot of studies on the incidence of hospital-acquired Acinetobacter baumannii infections. Abbreviations: HA-AB: hospital-acquired Acinetobacter baumannii, ICU: intensive care unit, 95% CI: 95% confidence interval. density of 0.16 (95% CI 0.14-0.19) HA-AB infections per 1,000 patient days, which was markedly lower than the ICU estimates.
Incidence of hospital-acquired carbapenemresistant Acinetobacter baumannii infections
Twelve studies provided data on the incidence of hospital-acquired infections with carbapenem-resistant A. baumannii (HA-CRAB). The pooled incidence of HA-CRAB cases was 21.4 (95% CI 11.0-41.3) cases per 1,000 patients in the EUR, EMR and AFR WHO regions ( Figure 4 ). Estimates of HA-CRAB incidences were substantially higher in studies exclusively conducted on ICUs compared to hospital-wide studies or studies carried out in specialist clinical departments with ICU and non-ICU patients. The pooled incidence of HA-CRAB infections in ICUs was 41.7 (95% CI 21.7-78.7) cases per 1,000 ICU patients, although a considerably high inter-study variation was observed (I 2 = 99%, p < 0.01). Much lower HA-CRAB infection rates were observed in one hospital-wide study (2.0 [95% CI 0.49-7.8] cases per 1,000 admissions) and in two studies conducted in specialist clinical departments Five studies provided data on the incidence density of hospital-acquired carbapenem-resistant A. baumannii infections on ICUs. The pooled estimate was 2.1 (95% CI 1.2-3.7) HA-CRAB cases per 1,000 ICU patient days ( Figure 5 ), with individual study estimates ranging between 0.63 and 5.4 cases per 1,000 patient ICU days. A considerable inter-study variation was observed (I 2 = 96%, p < 0.01). The study by Atilla et al. 2015 [44] which was conducted on a specialist burn unit with both ICU and non-ICU patients reported an incidence density of HA-CRAB infections of 3.5 per 1,000 patient days.
Proportions of hospital-acquired Acinetobacter baumannii infections among all healthcareacquired infections 21 incidence studies reported the proportion of A. baumannii as a causative agent for hospital-acquired infections. The pooled estimate of the proportion of A. baumannii associated infections among all HAIs was 15.3% (95% CI 11.7-19.7%) ( Figure 6 ). Similar to the analyses described above, the burden of A. baumannii was especially high in intensive care units, where A. baumannii infections accounted for 20.9% (95% CI 16.5-26.2%) of all hospital-acquired infections, although considerable inter-study variation was observed (I 2 = 96%, p < 0.01). In studies conducted in specialist clinical departments/wards comprised of ICU and non-ICU patients, the pooled estimate of the proportion of HA-AB infections among all HAIs was 16.3% (95% CI 8.0-30.5%). However, a large variance and inter-study variation (I 2 = 98%, p < 0.01) was found. As reported by three studies conducted at hospital-wide level, A. baumannii was responsible for 1.6% to 6.2% of all HAIs (pooled estimate: 5.3% [95% CI 3.2-8.6%]). In one study conducted solely on an internal medical ward, A. baumannii was identified as the causative pathogen in 1.6% of all HAIs. Although the proportion of HA-AB among all HAIs on ICUs observed in the EUR WHO region was about twice as large as in the EMR WHO region, the difference was not statistically significant (23.6% [95% CI 17.0-31.8%] vs. 12.0% [95% CI 2.8-38.8%], Q = 1.03, p = 0.310). Furthermore, no significant differences in the proportion of HA-AB among all HAIs in the ICU were found among country income levels (high income [four studies], upper-middle income [six studies] and lower-middle income countries [two studies], Q = 1.40, p = 0.4972).
Thirteen studies reported data on the proportion of carbapenem-resistant A. baumannii infections among all hospital-acquired infections (Figure 7) . In ICUs, the pooled proportion of HA-CRAB infections among all HAIs was 13.6% (95% CI 9.7-18.7%). However, a large inter-study variation was observed (I 2 = 97%, p < 0.01), with individual estimates ranging from 2.9% to 45.7%. There is evidence that the proportion of HAIs due to CRAB was much lower outside ICUs, as reported in one hospital-wide study and another conducted on an internal medical ward. Both studies found that 1.6% of all HAIs were caused by carbapenem-resistant A. baumannii. No comparison of WHO regions was performed since only one study from the AFR WHO region and none from the EMR WHO region were included in this subgroup analysis. Interestingly, in studies conducted in upper-middle income countries (n = 5) the proportion of HA-CRAB infections among all HAIs in the ICU was markedly higher compared to studies (n = 3) from high income countries (21.9% [95% CI 16.2-28.9%] vs. 8.8% [95% CI 4.8-15.6%], Q = 7.77, p = 0.0053).
Prevalence of hospital-acquired A. baumannii infections
Two multicenter hospital-wide point prevalence studies were included in this review that reported prevalences of 3.0 and 10.6, respectively, hospital-acquired A. baumannii infections per 1,000 patients. Interestingly, while Ahoyo et al. 2014 (Benin) [36] observed no infections with carbapenem-resistant A. baumannii, Kritsotakis et al. 2017 (Greece) [40] found that among all hospital-acquired A. baumannii infections, 92% were carbapenem-resistant, resulting in a HA-CRAB prevalence of 8.9 per 1,000 patients.
Both studies also provided hospital-wide data on the proportion of A. baumannii among all pathogens causing hospital-acquired infections. Kritsotakis et al. 2017 [40] reported that A. baumannii was responsible for 10.7% of all HAIs. In contrast, Ahoyo et al. 2017 [36] identified A. baumannii as the causative pathogen in only 1.3% of all HAIs.
Discussion
Hospital-acquired infections caused by Acinetobacter baumannii, particularly carbapenem-resistant strains, are a significant threat to health and patient safety worldwide as a result of the continuing decline in treatment options. This study is the first systematic review and meta-analysis to provide a comprehensive summary of recent data on the incidence and prevalence of nosocomial infections with (carbapenemresistant) Acinetobacter baumannii in the WHO-defined regions of Europe, Africa and the Eastern Mediterranean. Based on a review of 24 included studies published between 2014 and 2018, we show that hospital-acquired infections caused by Acinetobacter baumannii represent a significant risk to health for hospital patients in Europe, Africa and Eastern Mediterranean regions.
Importantly, the incidence of hospital-acquired AB infections is particularly high in ICUs, where the pooled estimate is as high as 56 HA-AB cases per 1,000 ICU patients and the pooled incidence density is 4.4 HA-AB cases per 1,000 patient ICU days. Due to vulnerable patients with severe comorbidities and high number of invasive procedures, ICUs are known hotbeds for healthcare-acquired infections, including Acinetobacter species [49, 50] . Our analyses showed that there are no systematic differences in the incidence of hospital-acquired A. baumannii infections in ICUs between the European and the Eastern Mediterranean WHO regions. It is important to note that our European study set is over-represented by countries located in the south-eastern part of the European WHO region. However, studies conducted in Italy and Poland found similar ICU incidence when compared to studies in Bosnia-Herzegovina, Turkey and countries from the EMR WHO-region.
In addition to the high incidence of HA-AB infections in ICUs, we found that the pooled incidence of carbapenem-resistant A. baumannii infections is 42 HA-CRAB cases per 1,000 ICU patients, with individual study estimates ranging between 7 and 213 cases per 1,000 ICU patients. In comparison, a recent systematic review reported incidences of 18-649 HA-CRAB cases per 1,000 ICU patients in Southeast Asia [51] . Importantly, the pooled HA-CRAB incidence observed in our study is only slightly lower than the total incidence of HA-AB infections, suggesting that the majority of hospital-acquired A. baumannii infections on ICUs are caused by carbapenem-resistant strains. This finding is particularly concerning since therapeutic options to treat CRAB infections are limited and these infections are generally associated with high morbidity, mortality and treatment costs [2, 3, 52] .
Not surprisingly, our study provides evidence that the incidence and prevalence of HA-AB infections is 10-50 times lower in hospital-wide studies compared to ICU-based studies. Two studies from Benin [36] and Greece [40] showed prevalence of 3 and 10.6 AB infections per 1,000 patients, respectively. In comparison, large multicenter studies from the United States and China reported prevalences of 0.7 HA-AB cases [53] and 3.2 HA-AB cases [54] per 1,000 patients, respectively. Moreover, evidence from a very recent study also shows that the prevalence of carbapenemnon-susceptible Acinetobacter spp. in the United States (0.3 cases per 1000 admissions) is lower than in the WHO-regions analysed in this study [55] .
The prominent role of hospital-acquired A. baumannii infections in ICUs is underlined by our finding that A. baumannii is the causative pathogen in more than 20% of all nosocomial infections. In fact, as shown by several large studies in our study set, A. baumannii is the most frequent organism to be responsible for nosocomial infections in the ICU, with higher infection rates than other clinically relevant pathogens, such as K. pneumoniae, E. coli and S. aureus [16, 25, 34] . This high proportion of A. baumanniiassociated HAIs on ICUs is also found in other parts of the world, including Southeast Asia [56] [57] [58] , China [59] and Latin America [60] . In addition, a review that examined studies between 1995 and 2008 from low and middle income countries also found that 19% of all HAIs are caused by Acinetobacter spp. in intensive care, and burn and transplant units [61] . In contrast, healthcare-acquired infections with Acinetobacter spp. are less prevalent on ICUs in the United States, where only 1.1% of all HAIs on ICUs are caused by Acinetobacter spp. [62] . According to 2016 data from The European Surveillance System (TESSy), Acinetobacter spp. causes only 2 -8% of HAIs in ICUs [63] in Europe; profoundly less than our estimates. These discrepancies may be explained by the fact that many Western and Northern European countries provide data on hospital-acquired infections in TESSy, while in our analysis studies from countries in these regions were disproportionately under-represented. TESSy data show that Acinetobacter spp. cause more HAIs in ICUs in eastern and southern countries compared to countries in northern and western regions of WHO-Europe. It is interesting that studies providing hospital-wide incidence estimates show that A. baumannii causes only 1.6 -6% of all hospitalacquired infections compared to 20% in the ICU (Figure 2 ). Other pathogens such as S. aureus and E. coli are more frequently found among hospitalacquired infections on a hospital-wide level than A. baumannii, as shown by several studies in Europe and Africa [37, 38, 42] . In comparison to our data, a large multicenter study including 52 hospitals found that 7.9% of all HAIs in China are caused by A. baumannii [54] . Interestingly, while our data indicate similar proportions of HA-AB infections among all HAIs between high (22%) and upper-middle (25%) income countries, we observed that HA-CRAB proportions among all HAIs are much lower in high income countries (9%) compared to upper-middle income countries (22%). These findings suggest that carbapenem resistance proportions of A. baumannii are much higher in the ICU in countries with uppermiddle income emphasizing the clinical relevance of HA-CRAB in the ICU of middle income countries.
There is a general dearth of recent studies investigating the burden of (carbapenem-resistant) Acinetobacter baumannii infections in the African WHO region. However, available evidence suggests the widespread prevalence of carbapenemase-producing bacteria in Africa, with prevalence ranging from 2.3% to 67.7% in North Africa, and from 9% to 60% in sub-Saharan Africa [64] . Studies to delineate the magnitude and spread of A. baumannii infections across Africa are therefore urgently needed. In addition, the Eastern Mediterranean region is affected by several difficulties that are complicating issues around the spread and control of antimicrobial resistance (AMR) [65] . It is not surprising that the burden of AMR and CRAB in particular remains high in this region, as identified in studies including our own [10] .
Strength and limitations
With 24 included studies and data from more than 280,000 hospitalized patients, our systematic review represents the largest study on the incidence and prevalence of hospital-acquired infections from (carbapenem-resistant) A. baumannii in the European, African and Eastern Mediterranean WHO regions. A major strength of our study is that we only included studies comprising of non-disease-specific patients from whole hospitals or individual wards, which ensured the representativeness of our estimates for these institutions and wards. However, our study has some limitations. Firstly, the country representativeness of the individual studies is unclear in most cases, which limits the external validity of our findings. Secondly, studies are not evenly distributed across the WHO regions. In particular, the WHO EUR study set is over-represented by studies from Turkey, while no studies from western and northern parts of Europe were included. Consequently, possible differences in (CR)AB incidence and prevalence between the EUR and EMR WHO regions may be masked by the geographical proximity of Turkey to the Eastern Mediterranean WHO region. Thirdly, due to the relatively low number of hospital-wide studies, our hospital-wide estimates of hospital-acquired A. baumannii infections are unlikely to be generalizable. Finally, we observed a large inter-study heterogeneity, particularly within the ICU study set, and the pooled effect sizes must therefore be interpreted with caution. Likely reasons for the large inter-study variations are differences in the distribution of underlying diseases among the included patient cohorts, surgical procedures, immune status and mechanical ventilation. These factors are associated with an increased risk of hospital-acquired infections [66] . Differences in environmental prevalence and colonization rates by Acinetobacter spp., both of which are understudied, may also affect HA-AB and HA-CRAB infection rates. In addition, we also recognize that it is difficult to adequately compare outcomes of pathogen-identification tests and antimicrobial susceptibility tests carried out across various regions due to non-standardization of definitions, infection sources and laboratory methods.
Conclusion
Our study stresses the relevance of hospital-acquired infections caused by A. baumannii, including infections with carbapenem-resistant strains, in the European, African and Eastern Mediterranean WHO regions. In particular, the evidence provided in our systematic review highlights the prominent role of A. baumannii as an "ICU pathogen", particularly in light of the high carbapenem-resistant rates observed in most of the included studies. This finding can guide ICUs to prioritize their allocation of resources for infection prevention and control, and in the stewardship of antibiotics, particularly those on the WHO's Essential Antibiotics Watch and Reserve categories [67] .
